Experimental Pathogenicity of a Clinical Isolate of Trichosporon dermatis in a Murine Model

2011 ◽  
Vol 172 (5) ◽  
pp. 381-387 ◽  
Author(s):  
Ying-Ping Lin ◽  
Yan-Ping Yang ◽  
Wen-Ming Huang ◽  
Yong-Hua Chen ◽  
Shun-Fan Li ◽  
...  
Author(s):  
Voahangy Andrianaivoarimanana ◽  
Lovasoa Nomena Randriantseheno ◽  
Kristoffer M Moore ◽  
Nicola J Walker ◽  
Steven G Lonsdale ◽  
...  

Abstract Two monoclonal antibodies directed to the V antigen of Yersinia pestis have been tested for protective efficacy in a murine model of bubonic plague. Mice were infected with a current clinical isolate from Madagascar, designated Y.pestis 10-21/S. Mab7.3, delivered to mice intra-periteoneally at either 24h prior to, or 24h post- infection, was fully protective, building on many studies which have demonstrated the protective efficacy of this Mab against a number of different clinical isolates of Y.pestis. Mab 29.3, delivered intra-peritoneally at either -24h or +24h, protected 4/5 mice in either condition; this has demonstrated the protective efficacy of this Mab in vivo for the first time. These results add to the cumulative data about Mab7.3, which is currently being humanized and highlight its potential as a human immunotherapeutic for plague, which is an enduring endemic disease in Madagascar and other regions of Africa, Asia and South America.


2012 ◽  
Vol 147 (2-3) ◽  
pp. 354-359 ◽  
Author(s):  
X.-H. Huyan ◽  
Y.-P. Yang ◽  
Y.-M. Fan ◽  
W.-M. Huang ◽  
W. Li ◽  
...  

2003 ◽  
Vol 71 (1) ◽  
pp. 516-523 ◽  
Author(s):  
Jon S. Blevins ◽  
Mohamed O. Elasri ◽  
Scott D. Allmendinger ◽  
Karen E. Beenken ◽  
Robert A. Skinner ◽  
...  

ABSTRACT We recently demonstrated that mutation of sarA in clinical isolates of Staphylococcus aureus results in a phenotype that is distinct by comparison to sarA mutants generated in the laboratory strain RN6390 (J. S. Blevins, K. E. Beenken, M. O. Elasri, B. K. Hurlburt, and M. S. Smeltzer, Infect. Immun. 70:470-480, 2002). This raises the possibility that studies demonstrating that RN6390 sarA mutants are attenuated do not accurately reflect the role of sarA in the pathogenesis of staphylococcal disease. To test this hypothesis, we used a murine model of musculoskeletal infection to assess the virulence of sarA and agr mutants generated in a clinical isolate of S. aureus (UAMS-1). By using this model, we confirmed that mutation of sarA and/or agr results in a reduced capacity to cause both septic arthritis and osteomyelitis.


1997 ◽  
Vol 17 (3) ◽  
pp. 131-138 ◽  
Author(s):  
Annie Sulahian ◽  
Yves Jean François Garin ◽  
Francine Pratlong ◽  
Jean Pierre Dedet ◽  
Francis Derouin

2001 ◽  
Vol 48 (2) ◽  
pp. 170-176 ◽  
Author(s):  
YVES J. F. GARIN ◽  
ANNIE SULAHIAN ◽  
PASCALE MENECEUR ◽  
FRANCINE PRATLONG ◽  
ERIC PRINA ◽  
...  

2000 ◽  
Vol 44 (6) ◽  
pp. 1624-1629 ◽  
Author(s):  
Janet Goldberg ◽  
Patricia Connolly ◽  
Carol Schnizlein-Bick ◽  
Michelle Durkin ◽  
Stephen Kohler ◽  
...  

ABSTRACT Nikkomycin Z was tested both in vitro and in vivo for efficacy against Histoplasma capsulatum. Twenty clinical isolates were tested for susceptibility to nikkomycin Z in comparison to amphotericin B and itraconazole. The median MIC was 8 μg/ml with a range of 4 to 64 μg/ml for nikkomycin Z, 0.56 μg/ml with a range of 0.5 to 1.0 μg/ml for amphotericin B, and ≤0.019 μg/ml for itraconazole. Primary studies were carried out by using a clinical isolate of H. capsulatum for which the MIC of nikkomycin Z was greater than or equal to 64 μg/ml. In survival experiments, mice treated with amphotericin B at 2.0 mg/kg/dose every other day (QOD) itraconazole at 75 mg/kg/dose twice daily (BID), and nikkomycin Z at 100 mg/kg/dose BID survived to day 14, while 70% of mice receiving nikkomycin Z at 20 mg/kg/dose BID and none of the mice receiving nikkomycin Z at 5 mg/kg/dose BID survived to day 14. All vehicle control mice died by day 12. Fungal burden was assessed on survivors. Mice treated with nikkomycin Z at 20 and 100 mg/kg/dose BID had significantly higher CFUs per gram of organ weight in quantitative cultures and higher levels of Histoplasma antigen in lung and spleen homogenates than mice treated with amphotericin B at 2.0 mg/kg/dose QOD or itraconazole at 75 mg/kg/dose BID. Studies also were carried out with a clinical isolate for which the MIC of nikkomycin Z was 4 μg/ml. All mice treated with amphotericin B at 2.0 mg/kg/dose QOD; itraconazole at 75 mg/kg/dose BID; and nikkomycin Z at 100, 20, and 5 mg/kg/dose BID survived until the end of the study at day 17 postinfection, while 30% of the untreated vehicle control mice survived. Fungal burden assessed on survivors showed similar levels ofHistoplasma antigen in lung and spleen homogenates of mice treated with amphotericin B at 2.0 mg/kg/dose QOD; itraconazole at 75 mg/kg/dose BID; and nikkomycin Z at 100, 20, and 5 mg/kg/dose BID. The three surviving vehicle control mice had significantly higher antigen levels in lung and spleen than other groups (P < 0.05). The efficacy of nikkomycin Z at preventing mortality and reducing fungal burden correlates with in vitro susceptibility.


2004 ◽  
Vol 72 (11) ◽  
pp. 6702-6706 ◽  
Author(s):  
Guiqing Wang ◽  
Radha Iyer ◽  
Susan Bittker ◽  
Denise Cooper ◽  
Jennifer Small ◽  
...  

ABSTRACT The effects of variations in Barbour-Stoenner-Kelly (BSK) medium on the infectivity and pathogenicity of Borrelia burgdorferi clinical isolates were assessed by retrospective and prospective studies using a murine model of Lyme borreliosis. Thirty of 35 (86%) mice infected with any of six virulent B. burgdorferi clinical isolates grown in a BSK-H medium developed clinically apparent arthritis. By contrast, arthritis was observed in only 25 of 60 (42%) mice inoculated with two of these B. burgdorferi strains grown in a different lot of BSK-H medium (P < 0.001). In a prospective study, mice inoculated with a B. burgdorferi clinical isolate grown in a BSK medium prepared in-house produced significantly greater disease than those injected with the same isolate cultured in BSK-H medium (P < 0.05). The attenuated pathogenicity is not due to the loss of plasmids during in vitro cultivation. The data suggest that variations in BSK medium have a significant impact on the infectivity and pathogenicity of B. burgdorferi clinical isolates.


2018 ◽  
Vol 86 (11) ◽  
Author(s):  
Gregory Hall ◽  
Shinichiro Kurosawa ◽  
D. J. Stearns-Kurosawa

ABSTRACTShiga toxin-producingEscherichia coli(STEC) bacteria are globally important gastrointestinal pathogens causing hemorrhagic gastroenteritis with variable progression to potentially fatal Shiga toxicosis. Little is known about the potential effects ofE. coli-derived Shiga-like toxins (STXs) on host gastrointestinal immune responses during infection, in part due to the lack of a reproducible immunocompetent-animal model of STEC infection without depleting the commensal microbiota. Here, we describe a novel and reproducible murine model utilizing dextran sulfate sodium (DSS) colitis to induce susceptibility to colonization with clinical-isolate STEC strains. After exposure to DSS and subsequent oral STEC challenge, all the mice were colonized, and 66% of STEC-infected mice required early euthanasia. Morbidity during STEC infection, but not infection with an isogenic STEC mutant with toxin deleted, was associated with increased renal transcripts of the injury markersKIM1andNGAL, histological evidence of renal tubular injury, and increased renal interleukin 6 gene (IL-6) andCXCL1inflammatory transcripts. Interestingly, the intestinal burden of STEC during infection was increased compared to its isogenic Shiga toxin deletion strain. Increased bacterial burdens during Shiga toxin production coincided with decreased induction of colonic IL-23 axis transcripts known to be critical for clearance of similar gastrointestinal pathogens in mice, suggesting a previously undescribed role for STEC Shiga toxins in suppressing host immune responses during STEC infection and survival. The DSS+STEC model establishes infection with clinical-isolate strains of STEC in immunocompetent mice without depleting the gastrointestinal microbiota, enabling characterization of the effects of STXs on the IL-23 axis and other gastrointestinal pathogen-host interactions.


2001 ◽  
Vol 120 (5) ◽  
pp. A685-A685
Author(s):  
B SINGH ◽  
V MALMSTROM ◽  
F POWRIE

Sign in / Sign up

Export Citation Format

Share Document